BL-M02D1 vs Sacituzumab Govitecan

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: TROP2 · full Non-Small Cell Lung Cancer pipeline

BL-M02D1

Developed by Sichuan Baili Pharmaceutical

Phase 1/2 in Non-Small Cell Lung Cancerantibody-drug conjugate
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Sacituzumab Govitecan

Marketed by Gilead Sciences and partners

Phase 3 in Non-Small Cell Lung Cancerantibody-drug conjugate
Partial signal

NCT05089734 · Phase 3 · active, not recruiting

This was a randomized, open-label Phase 3 trial of 603 patients comparing sacituzumab govitecan to docetaxel, using overall survival (a hard clinical endpoint) as the primary measure. Although the drug showed a numerical survival advantage (11.1 vs 9.8 months), the difference did not reach statistical significance (p=0.0534), so the trial's primary comparison was not formally met despite a reasonably strong and adequately powered design.

Next expected readout: January 2027 · NCT05609968 (registry estimate)

Reported efficacy

Overall Survival (OS) (Up to 24.4 months): EVOKE-01 (NCT05089734), primary endpoint overall survival: sacituzumab govitecan 11.1 months vs docetaxel 9.8 months; not statistically significant (missed)

Result source: NCT05089734

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBL-M02D1Sacituzumab Govitecan
PFS, median—Not reported—Trial running · NCT05609968
OS, median—Not reported—Trial running · NCT05609968
ORR—Not reported—Trial running · NCT05609968
Duration of response, median—Not reported—Trial running · NCT05609968

PFS, median

BL-M02D1
—Not reported
Sacituzumab Govitecan
—Trial running · NCT05609968

OS, median

BL-M02D1
—Not reported
Sacituzumab Govitecan
—Trial running · NCT05609968

ORR

BL-M02D1
—Not reported
Sacituzumab Govitecan
—Trial running · NCT05609968

Duration of response, median

BL-M02D1
—Not reported
Sacituzumab Govitecan
—Trial running · NCT05609968
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

BL-M02D1: no structured comparison results are available for Non-Small Cell Lung Cancer.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Sacituzumab Govitecan
EVOKE-01 (NCT05089734), primary endpoint overall survival: sacituzumab govitecan 11.1 months vs docetaxel 9.8 months; not statistically significant NCT05089734 · Phase 3 · design grade: moderate · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. BL-M02D1: 0 of 4 rows · Sacituzumab Govitecan: 1 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricSacituzumab Govitecan
Dropout rate
4.8%10 mg/kga
NCT01631552 · Phase 1/2 · registry result, not featured evidence
Discontinued due to AEs
—10 mg/kga
NCT01631552 · Phase 1/2 · registry result, not featured evidence
Serious AEs
—10 mg/kga
NCT01631552 · Phase 1/2 · registry result, not featured evidence
Most frequent reported AEs—

Notes

  1. aPopulation comparability has not been reviewed for these studies.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BL-M02D1's landscape · Sacituzumab Govitecan's landscape